Key words: bronchi, dose-response curve, histamine, H,-receptor antagonist, Hireceptor antagonist. 1. Nine normal subjects inhaled increasing concentrations of histamine aerosol from an aerosol generator attached to a breath-actuated dosimeter. The responses were monitored by measuring specific airwaysconductance in a body plethysmograph, and the results were expressed as cumulative log dose-response curves. On separate days, histamine challenges were repeated after intravenous injections of sodium chloride solution (placebo), or an HI-receptor antagonist chlorpheniramine, or an H,-receptor antagonist cimetidine, or HI-and H,-receptor antagonists together. The anticholinergic activity of chlorpheniramine was estimated by comparing the effect of chlorpheniramine and atropine on methacholine challenge.
Introduction
In 1929, Weiss, Robb & Blumgart found that histamine was a powerful bronchoconstrictor in asthmatic subjects. Their findings were extended by Curry (1946) and Herxheimer (1951), both of whom advocated the use of existing antihistamines for the treatment of asthma. In contrast, others, including Karlin (1972), concluded that these drugs were of little therapeutic value.
The concept of two distinct populations of histamine receptors, the HI-and H,-receptors, was first proposed by Ash & Schild (1966) , who suggested that receptors antagonized by conventional antihistamines (e.g. mepyramine) should be designated HI-receptors. The synthesis of burimamide, by Black, Duncan, Durant, Ganellin & Parsons (1972) . and the subsequent development of metiamide and cimetidine has recently allowed definition of the histamine H,-receptor.
Maegwyne-Davis (1968), Eyre (1969), Krell & Chakrin (1977) , Chand & Eyrc (1977) and Okpako, Chand & Eyre (1978) have identified HIand H,-receptors in the tracheobronchial tree of the cat, sheep, guinea pig, dog and horse. Dunlop & Smith (1977) have suggested, as a result of studies in oirro, that both types of receptors are present in bronchial smooth muscle in man.
The present study was designed to determine whether both types of receptors could be demonstrated in the normal human bronchus in oiuo, and whether, if present, H,-receptors mediated 537 0143-5221/80/06053148S1.S0/1 bronchodilatation or bronchoconstriction. The effect of both the HI-receptor antagonist chlorpheniramine and the H,-receptor antagonist cimetidine on bronchial challenge with histamine, has been studied in non-asthmatic subjects. The results of these challenges were expressed as dose-response curves.
Method
Nine normal subjects (Table 1) were studied. They were all laboratory workers who gave informed consent for these investigations. None had respiratory infections at the time of the study, nor during the preceding month. The response of the airways to the inhaled histamine was monitored by serial measurements of specific ainvaysconductance (sGaw), measured in a constant-volume body plethysmograph by the method of Dubois, Botellho & Comroe (1956 ). An extra port was constructed in the front of the plethysmograph through which the challenge ,aerosol was inhaled (Fig. 1) . A breath-activated 'dosimeter' (Rosenthal, Norman, Summer & Permutt, 1977) delivered a standardized quantity of aerosol to the subject. As the subject breathed in the change in mouth pressure triggered the dosimeter and regulated air flow at a pressure of 23 kg/cm, for 0.6 s, through a solenoid valve to a Hudson nebulizer; the nozzle of the nebulizer was directed through the port and was 36 cm from the mouth. The subject was asked to inhale the aerosol to a similar depth, near to vital capacity, and at the same rate during each challenge.
Histamine dose-response challenges were performed as follows: after four measurements of sGaw had been made the subject inhaled histamine acid phosphate (five breaths, each of 2 g/l), 2 min later, sGaw was measured three to four times.
Every 2f3 min the subject inhaled double the previous doses of histamine, up to a final concentration of 64 g/l. The nebulizer was washed and dried. between each dose. The duration of the challenge was between 15 and 20 min. Any subject wheezy at the end of the challenge was given salbutamol aerosol (100 pg).
On separate days the histamine challenges were repeated, either after no premedication or 10 min after intravenous injections of sodium chloride solution (150 mmol/l: saline placebo), chlorpheniramine (20 mg), cimetidine (200 mg), cimetidine (400 mg) or chlorpheniramine (20 mg) with cimetidine (200 mg). Each subject had seven histamine challenges in random order. This was a single blind study, i.e. the subjects were ignorant of 
Aerosol characteristics
The extra port of the plethysmograph represented a relatively large dead-space separating the nebulizer outside and the subjects' mouth inside the plethysmograph. In order to establish how much aerosol was lost within the port during inhalation, and whether that loss was constant, the nebulizer containing water was triggered 50, 100 and 250 times during simulated quiet breathing. The aerosol was absorbed by anhydrous calcium chloride in a receptacle at the mouthpiece. Absorption of aerosol within the port was negligible (Fig. 2a) . The frequency-distribution of the aerosoldroplet size was determined by measuring the craters made by the aerosol on a slide coated with magnesium oxide held at the mouthpiece (Sellick & Widdicombe, 1971; Jain, 1975). Of droplets counted 89% were between 6 and 15 pm in diameter, with a peak at 8 pm (Fig. 2b) .
Data analysis and statistical validation
The response to histamine challenge was expressed as a dose-response curve. Preliminary studies had shown that the maximum effect of a single dose of histamine occurred after 1 min and was maintained for 20 min. Since the duration of the challenge was 15-20 min, cumulative doseresponse curves were drawn. The responses to both histamine and methacholine challenge were expressed in absolute values of sGaw. In addition the response to histamine was expressed as a percentage of baseline since there was relatively little variation in baseline sGaw between subjects.
Analysis of variance was used to compare the effects of the antihistamines on subsequent challenges.
Each value of sGaw in this study was the mean of four measurements. For each value the SD and the coefficient of variation were calculated. As an expression of reproducibility of these measurements in the two unpremedicated histamine challenges, the mean and the ranges of these SD values and coefficients of variation for all nine subjects were obtained in the resting state and after 300 and 1260 pg of histamine ( Table 2) reproducibility of the unpremedicated histamine challenges was determined by calculating a correlation coefficient and a paired t-test in each subject for results from the responses to the two challenges with the seven doses of histamine (0-1260 pg) ( Table 3) . Mean curves were derived from the data in all nine subjects to give overall group dose-response curves for each challenge. The two group curves were also compared by using a correlation coefficient and a paired 1-test.
There was considerably more inter-subject variation in response to methacholine than to histamine. In order to use the method of analysis of variance to compare the effect of the blocking drugs on the methacholine response, the effective dose was normalized in the following way. From each subject's mean methacholine dose-response curve, the dose of methacholine needed to reduce baseline sGaw by 20% was found and designated 'cumulative unit 1'. At multiples of 2 and 4 of this cumulative unit, sGaw was read off the mean methacholine curve. sGaw was then read off the methacholine challenges premedicated with chlorpheniramine and atropine at cumulative units 1, 2 and 4. This process was repeated for each subject. Since the derived units were independent of the dose given, inter-subject comparison was possible.
Results

Reproducibility
The reproducibility of the measurements of sGaw is shown in Table 2 . The overall coefficient of variation, the mean of the three shown, was 7%. Table 3 shows the reproducibility of the two histamine challenges. With the exception of subject no. 4, there was a highly significant correlation between the two unpremedicated histamine challenges, showing that the shapes of the two challenge curves were similar. The correlation of the mean dose-response curves was also high. The results of the paired t-tests indicated that there was no significant difference between the two mean histamine responses, but the individual subject's t-tests showed that subjects nos. 6 and 9 had a difference in response to the two challenges. The significant correlations in these subjects, however, indicated that the shapes of the challenge curves remained similar despite this shift.
Baseline sGaw and the effect of antihistamines The mean baseline sGaw values for all challenges in each subject are given in Table 1 . Though there was relatively little intra-subject variability the inter-subject variation was large; in these subjects mean baseline sGaw values ranged between 1-33 and 2-47 s-l kPa-'. Neither the antihistamines nor the saline placebo injection produced significant changes in the mean baseline sGaw values (Fig.  3a) .
Effect of antihistamines on histamine response
The mean results for all nine subjects are shown in Fig. 3 with cumulative dose of histamine (pg) plotted on log scale against sGaw (s-' kPa-') in Fig. 3(a) and as a percentage of baseline sGaw value in Fig. 3(b) . As seen in Fig. 3 the mean histamine dose-response curve in the normal subjects had a threshold at about 140 pg of histamine and a subsequent slope. Some subjects felt wheezy and dyspnoeic alter the final dose of histamine. From an analysis of variance the least significant difference at the P = 0.05 and P = 0.01 level was found for the mean of results calculated in absolute and percentage values. Differences greater than these indicated a signiAcant shift of the dose+ response curve. Saline placebo did not significantly alter the histamine dose-response curve. There was a very small shiR to the right with cimetidme (200 and 400 mg), but this attained statistical significance (P < 0.05, Fig. 3a ; P < 0.01, Fig. 36 ) with cimetidme (400 mg) only at the highest dose of histamine. However, chlorpheniramine, both alone and in combination with cimetidine, produced much larger shiRs to the right of the histamine doseresponse curve. This was statistically significant at 
Anticholinergic effects of chlorpheniramine
During the methacholine studies (Fig. 4) , premedication with atropine raised the baseline sGaw value significantly by a mean of 44% and completely abolished the response to methacholine. Chlorpheniramine produced a smaller (22%) but statistically significant rise in baseline sGaw value. However, chlorpheniramine appeared to have no effect on the methacholine dosMesponse curve; the separation of the two curves after cumulative units 1,2 and 4 was smaller than the separation of the baseline values of sGaw.
Side-effects of antihistamines
Chlorpheniramine (20 mg) .produced varying degrees of drowsiness in all subjects. No sideeffects were seen after the injection of cimetidine (200 mg). However, cimetidine (400 mg) and chlorpheniramine (20 mg) with cimetidme (200 mg) caused a transient metallic taste in the mouth of some subjects.
Discussion
Methodology
In this study a quantified reproducible dose of histamine aerosol was given by connecting the dosimeter to a Hudson nebulizer, following the principles for bronchial inhalation-challenge procedures (Chai, Farr, Froehlich, Mathison, McLean, Rosenthal, Sheffer, Spector & Townley, 1975) . The particles from the nebulizer were of a suitable size to reach the smaller airways. sGaw was chosen as a measure of airways obstruction because it is effort-independent and does not require full inspiration, which may alter airways calibre (Nadel & Tierney, 1961; Orehek, Gayrard, Grimaud & Charpin, 1975) . sGaw is sensitive to small changes in large airways calibre (Lloyd & Wright, 1963; Cohen & Hale, 1965) . We found that the measurements of sGaw were reproducible.
Since large doses of chlorpheniramine caused drowsiness in subjects, it was thought unethical for the investigator to be ignorant of the nature of the drugs received by the subjects; the study was undertaken, therefore, in a single-blind fashion.
Dose-response curve
The response to histamine challenge was expressed as a dose-response curve, rather than a single arbitrary end point, since it not only characterizes the effect of the drug more completely (Goldstein, Aronow & Kalman, 1968) but also enables comparisons to be made between responses (Orehek et al., 1975) . The use of single dose-response relationships in comparing results is valid only if the dose-response curves are parallel. A parallel shift to the right represents the extent of competitive antagonism. Dose-response curves obtained from strips of muscle in vitro have a threshold, slope and maximum response. In this study in vivo, the shape of the histamine dose-response curve was similar, except that it was impossible to increase the histamine dose sufficiently to reach a maximal response.
At the doses used, chlorpheniramine either alone or with cimetidine produced complete blockade of the histamine response in most subjects and so there was no final slope to the mean histamine response in the presence of chlorpheniramine; this fact precluded distinguishing differences in effect of chlorpheniramine, with or without cimetidine. In order to do this, a final slope of the histamine dose-response curve could have been obtained by either giving much larger doses of histamine or much smaller doses of chlorpheniramine.
Inter-subject comparison is difficult when there is a wide variation of responsiveness. In previous studies, where single dose-response relationships were examined, a 'provocation dose' of challenge aerosol, resulting in a predetermined bronchoconstrictor response, was used to make such comparisons. Thus Rosenthal el al. (1977) compared in different subjects the cumulative dose of antigen that produced a 35% fall in sGaw (PD,,) . In the present methacholine-challenge study, wide variations in sensitivity were found, and a similar technique was used on the whole curve to 'normalize' the effective dose.
Statistical analysis
Since the curves were not parallel, it was not possible to calculate the dose-ratios (the horizontal separation of the slopes of the mean histamine curves). Instead analysis of variance was chosen for this study because of its statistical efficiency in dealing simultaneously with both intra-and intersubject variability (Armitage, 197 1) .
In this study the small number of subjects, and the relatively large inter-subject variation in baseline, gave large values for the least-significant difference when the analysis of variance was applied to the mean data in absolute values of sGaw. Nevertheless, the blocking action of 400 mg of cimetidine was still statistically significant at the 5% level at the highest dose of histamine. Since the intra-subject variability in baseline was small the data were also calculated in percentage terms to allow for the large inter-subject variation of baseline sGaw; when this was done the effect of 400 mg of cimetidine became statistically significant at the 1% level.
Dosage and other effects of antihistamines
The dose of chlorpheniramine (20 mg) was chosen since it produced no further effect on the histamine dose-response curve than did 10 mg and so was judged to have blocked the H,-receptors maximally. Burland, Duncan, Hesselbo, Mills, Sharp, Haggie & Wyllie (1975) have demonstrated 75% inhibition of stimulated gastric secretion, with an intravenous infusion of cimetidine (100 mg/h), but it was not known what bolus dose was needed to antagonize fully any H,-receptors present in the, airways. In this study it appeared that 200 mg of cimetidine did not completely block the bronchial H,-receptor, since 400 mg had a larger effect on the histamine dose-response curve.
Chlorpheniramine produced no significant change in mean baseline sGaw value before the histamine challenges but produced a significant rise in this value (mean 20%) before methacholine challenges. In general, the higher the initial baseline sGaw the less was the rise cawed by chlorpheniramine. Four subjects had higher prechlorpheniramine baseline sGaw values in the histamine-challenge studies than in the methacholine-challenge studies, and this may have contributed to the negligible mean effect of chlorpheniramine on the baseline in the histamine studies. Thus in these four normal subjects chlorpheniramine had no consistent effect on resting bronchial tone. This agrees with the results of Maconochie, Woodings & Richards (1979) . In asthmatic subjects there are conflicting reports on the effects of HI-receptor antago&sts on bronchial tone. Hawkins (1955) found that many HI-antagonists released histamine and caused bronchoconstriction, but that there was no correlation between this and their antihistamine activity. Conversely, bronchodilatation was caused in asthmatic subjects given chlorpheniramine (Popa, 1977) , diphenhydramine (Casterline & Evans, 1977) or clemastine (Nogrady, Hartley, Handslip & Hurst, 1978), although Partridge & Saunders (1979) observed no effect with clemastine.
The transient metallic taste in the mouth of some subjects caused by chlorpheniramine and cimetidine together and by the larger dose of the H,-receptor-antagonist cimetidme (400 mg), may indicate the release of some endogenous histamine, since this taste has been described during histamine infusions (Lorenz & Doenicke, 1978) . Thermann, Lorenz, Schmal, Schingale, Dormann & Hamelmann (1977) have described endogenous histamine release after administration of HI-and H,-receptor antagonists in dogs. Nevertheless, this effect must have been trivial in our normal subjects since, after injections of antagonists together, sGaw rose in six subjects, was unchanged in two and fell by only 9% in one subject.
The role of the parasympathetic nervous system in the bronchial response to histamine is disputed (Colebatch, Olsen & Nadel, 1966; Sellick & Widdicombe, 1971; Casterline, Evans & Ward, 1976) . Results of a study in dogs (Sampson & Vidruk, 1979) suggest that the stimulation of airway rapidly adapting afferent vagal receptors by histamine is mediated by H,-receptors. With our methacholine challenges we have demonstrated that chlorpheniramine produced no significant anticholinergic effects in our subjects. The effect of chlorpheniramine on the histamine response was thus by H,-receptor antagonism. Since this effect was so marked, our results also imply that the H,-receptor is likely to be of primary importance in the histamine response.
The evidence from this study suggests that there may be H,-receptors in normal human airways but that the effect of the H,-receptor is predominant. Both types of histamine receptors appear to mediate bronchoconstriction. Casterline & Evans (1977) have also demonstrated the presence of HI-bronchoconstrictor receptors in asthmatic bronchi in uiuo, but did not look for evidence of H,-receptors. However, although the studies in uirro of Dunlop & Smith (1977) on sensitized human bronchi showed both types of histamine receptor in man, their results suggested that HI-receptors were bronchoconstrictors and H,-receptors bronchdiators. Further studies should be undertaken to investigate the status of histamine receptors in asthmatic subjects and their role in antigen challenge.
